Welcome to our dedicated page for Alkermes plc news (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes plc stock.
Alkermes Inc. plc (NASDAQ: ALKS) is a global biopharmaceutical company dedicated to developing innovative medicines for treating central nervous system (CNS) diseases. Headquartered in Dublin, Ireland, Alkermes has a significant presence in the United States with a research and development center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. The company’s mission is to leverage its proprietary technologies to create and commercialize pharmaceutical products that address unmet medical needs in conditions such as schizophrenia, depression, addiction, and multiple sclerosis.
Alkermes’ diversified product portfolio includes notable medications like LYBALVI®, ARISTADA®, and VIVITROL®. These products are pivotal in the treatment of mental health disorders and substance abuse, demonstrating the company's commitment to enhancing patient outcomes. LYBALVI®, a combination of olanzapine and samidorphan, is used for treating schizophrenia and bipolar I disorder. ARISTADA® is an extended-release injectable suspension for schizophrenia, and VIVITROL® is used for alcohol and opioid dependence.
The company's robust clinical pipeline features breakthrough candidates such as ALKS 2680, an investigational orexin 2 receptor agonist targeting narcolepsy. Recent study results announced in early 2024 have shown promising improvements in wakefulness for patients with narcolepsy type 2 and idiopathic hypersomnia, validating the potential of ALKS 2680 to address critical gaps in treatment.
Alkermes has also engaged in significant corporate developments, including the sale of its Athlone, Ireland facility to Novo Nordisk, aimed at increasing operational efficiency. Financially, the company reported total revenues of $1.66 billion for 2023, with a net income of $356 million, emphasizing strong growth and profitability. The company's strategic focus on neuroscience and operational efficiency is expected to drive sustained profitability and innovation in treating CNS disorders.
For more detailed information about Alkermes’ products, clinical trials, and corporate strategies, you can visit their official website at www.alkermes.com.
Alkermes plc (Nasdaq: ALKS) announced its participation in a fireside chat at the BofA Securities 2022 Biotech SMID Cap Conference, scheduled for December 7, 2022 at 8:00 a.m. ET. The session will be available via webcast on the company's website and archived for 14 days. Alkermes is focused on developing innovative medicines in neuroscience and oncology, with products targeting alcohol and opioid dependence, schizophrenia, and bipolar disorder. The company operates globally with facilities in Dublin, Massachusetts, Ireland, and Ohio.
Alkermes plc (Nasdaq: ALKS) will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on November 29, 2022, at 2:40 p.m. ET. The event will be accessible through a live webcast on Alkermes’ investor page, with an archived version available for 14 days post-event. Alkermes is a global biopharmaceutical company focused on innovative medicines for neuroscience and oncology, with a diverse portfolio aimed at treating alcohol dependence, opioid dependence, schizophrenia, and bipolar disorder.
Alkermes plc (Nasdaq: ALKS) announced participation in a fireside chat at the Stifel 2022 Healthcare Conference on November 15, 2022, at 8:00 a.m. ET. The live webcast will be accessible on the company's website and archived for 14 days.
Alkermes is a global biopharmaceutical company focused on developing innovative treatments in neuroscience and oncology, with products aimed at alcohol and opioid dependence, schizophrenia, and bipolar disorder.
Alkermes plc (ALKS) reported Q3 2022 revenues of $252.4 million, a decline from $294.1 million year-over-year. Net sales of proprietary products rose to $199.4 million, driven by LYBALVI's launch, achieving $27.1 million. However, GAAP loss per share was $0.39, up from $0.18 a year earlier. The company plans to separate its neuroscience and oncology businesses. Financial guidance for 2022 has been raised, citing LYBALVI's performance and updates on long-acting INVEGA royalties.
Alkermes plc (Nasdaq: ALKS) plans to separate its commercial-stage neuroscience business from its development-stage oncology business to enhance focus, allocate capital effectively, and create distinct investment profiles. This strategic decision is expected to unlock shareholder value by allowing each business to pursue tailored growth strategies. The separation, anticipated in the second half of 2023, will enable Alkermes to concentrate on its neuroscience products while the new Oncology Co. will develop cancer therapies, including the investigational drug nemvaleukin. Financial details will follow.
Acorda Therapeutics reported its Q3 2022 financial results, showing a net revenue increase for both INBRIJA and AMPYRA. INBRIJA U.S. sales reached $7.8 million, up 1% year-over-year, while AMPYRA revenue rose 5% to $21.1 million. The company secured a $16.5 million arbitration award from Alkermes, relieving it from royalty payments on AMPYRA. A special stockholders meeting is scheduled for November 4, 2022, to authorize a reverse stock split to avoid Nasdaq delisting. The 2022 guidance remains unchanged, with projected AMPYRA revenue between $68-78 million.
Alkermes plc (Nasdaq: ALKS) announced the recipients of the 2022 Alkermes Inspiration Grants, awarding funding to nine nonprofit organizations addressing addiction, serious mental illness, and cancer. The grants focus on historically under-resourced communities and received nearly 250 applications. Since 2016, the program has awarded over $4.5 million to support innovative health initiatives. CEO Richard Pops highlighted the potential impact of these programs for communities across the U.S.
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast on November 2, 2022, at 8:00 a.m. ET to discuss its third quarter financial results. The event will include updates from management regarding the company's performance. Interested parties can access the webcast through the Alkermes website and can dial in using the provided phone numbers. A replay will be available shortly after the event. Alkermes develops innovative medicines for neuroscience and oncology, with a focus on conditions such as alcohol and opioid dependence.
Acorda Therapeutics secured a favorable ruling from a three-judge arbitration panel against Alkermes PLC, with a monetary award of $15 million plus $1.5 million in pre-judgment interest. The decision relieves Acorda from paying royalties on AMPYRA sales, allowing them to source AMPYRA at competitive rates. This will enhance their profit margins and support ongoing services for patients with multiple sclerosis.
Alkermes plc (Nasdaq: ALKS) has opened applications for its 5th Annual Alkermes Pathways Research Awards, offering grants of up to $100,000 for early-career researchers focused on schizophrenia and bipolar disorder. The application period runs until Nov. 30, 2022. This initiative aims to support research addressing critical public health issues. Award recipients will be selected by an independent committee and have previously contributed to significant advancements in neuroscience. For eligibility details, visit www.PathwaysResearchAwards.com.
FAQ
What is the current stock price of Alkermes plc (ALKS)?
What is the market cap of Alkermes plc (ALKS)?
What does Alkermes Inc. plc specialize in?
What are some key products of Alkermes?
Where is Alkermes headquartered?
What recent achievements has Alkermes announced?
How did Alkermes perform financially in 2023?
What strategic moves has Alkermes made recently?
What is ALKS 2680?
What initiatives support Alkermes' commitment to mental health?
How can I get more information about Alkermes?
What partnerships or collaborations is Alkermes involved in?
